23 October 2018 - 24 October 2018
1:30 PM - 4:30 PM EST
Registration for this event has closed
HBA NEW YORK PRESENTS

Tissue-Agnostic Cancer Drug Development: An Emerging Paradigm Shift?

For many years, the oncology community has desired to treat tumors according to their genetic profile rather than basing treatment solely on the tissue involved. To realize this vision, 'basket' clinical trials are increasingly used to test different tumors in a single trial based on a shared biomarker or mutation. The best example of this, and the first FDA-approved “tissue-agnostic” indication, is Keytruda in MSI-high tumors (approved in 2017). Additional high-profile therapies using the basket trial approach include Loxo Oncology’s LOXO101 in TRK+ tumors, Ignyta’s entrectinib, also in TRK+, and AbbVie’s Rova-T, in DLL3-expressing tumors. The increasing number of tissue-agnostic indications presents several potential challenges and important questions for clinicians, payers, and for industry. Join us for a thought-provoking presentation and discussion on the current landscape for tissue-agnostic oncology products, and implications for stakeholders across the health ecosystem.

Agenda
5:30 - 6:00 PM    Networking
6:00 - 6:10 PM    Welcome and opening remarks
6:10 - 6:15 PM    Speaker introductions
6:15 - 7:15 PM    Panel discussions
7:15 - 7:30 PM    Q&A
7:30 - 8:00 PM    Closing remarks and additional networking

Registration information
Event is open to: HBA members and nonmembers
Online registration deadline: 23 October 2018
Onsite (walk-in) registration: Is allowed
    *To register onsite, please use a smartphone or other device; show your emailed receipt as proof of registration.

This event is nonrefundable.

Learning Objectives

1. Understand the clinical pipeline for tissue-agnostic approvals, and identify the tipping point when a sufficient number become available and start to influence the industry
2. Describe how a tumor-agnostic approach would affect some of the systems that exist in the management of oncology
3. Discuss the impact of this trend on various stakeholders in the health ecosystem in the near-term (e.g., HCPs, payers, regulatory, industry, etc.)

Featured Speakers

Chris Boshoff
SVP and head of early development and translational oncology, Pfizer Inc.
Geeta Devgan
Medical director, US medical affairs, Pfizer Oncology, Pfizer Inc.
David Hyman
Medical oncologist, Memorial Sloan-Kettering Cancer Center
Leigh Marcus
Pediatric Hematologist/Oncologist, Medical Officer, , U.S. Dept of Health & Human Services, Food & Drug Adminstration
Nitin Patel
Senior Principal, Consulting Services, IQVIA
Jillian Scaife
Principal,

Event Sponsor



Pricing

 MemberNon-Member
Regular registration$35.00 / €30.00$55.00 / €47.00

Members receive up to 50 percent discount



Event Policies

Photography Policy
By registering for this event, you acknowledge that you may be photographed, videotaped, and/or audio-taped during the meeting and hereby give permission for your image, voice, or survey comments to be used in education, training, promotion, and/or trade and communications media by the Healthcare Businesswomen's Association in any and all media throughout the world, without restriction as to frequency or duration of usage.

COVID-19 Policy
The HBA requires that all persons who participate in in-person events do so at their own risk and that each participant agrees to the following agreement before taking part in the activity and urges all participants to act in such a manner as to protect their own safety and the safety of others.

By registering for this event, I fully understand that my participation in the program is purely voluntary. I desire to participate and agree to act reasonably and prudently under the circumstances. I further understand that any HBA volunteers participating in the activity will act individually and will not represent the HBA. As a condition to my participation the activity, I waive and release the HBA and their officers, employees, and agents from any claim that I may have for any damage to property or injury to my person that may result in whole or in part from my participation.

Special Needs Policy
The HBA will make reasonable modifications to policies and programs to ensure that people with special needs can enjoy all of its programs. Contact us if you require special accommodations for this event.